CD177 and neoplasm: The cell surface receptor HER2/neu, also known as ErbB2, is an important tumormarker and the best studied target for designing novel therapeutic agents,since it is overexpressed in many tumor types (including human breast cancercells) and is associated with the aggressive tumor phenotype[3, 4].